Blueprint Medicines (NASDAQ:BPMC)

CAPS Rating: 5 out of 5


How do you think BPMC will perform against the market?

Add Stock to CAPS Watchlist

All Players

21 Outperform
0 Underperform

All-Star Players

10 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top BPMC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


BPMC Summary

Fools bullish on BPMC are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about BPMC.


Member Avatar TMFEBCapital (62.33) Submitted: 6/1/2018 10:50:57 AM : Outperform Start Price: $83.99 BPMC Score: -26.72

The company faces stiff competition from LOXO in developing RET targeting cancer treatment and LOXO has the pole position at ASCO over the coming days because of an oral presentation it's making. That could weigh down BPMC shares in the short-term, but this company's RET data is also compelling. Additionally, its CEO is the former President of Algeta -- a company that developed Xofigo and was sold to Bayer. With proven management and a good shot at a game-changing approach to medicine, I think this one will be a one-time winner, despite the risk of a short-term drop.


Member Avatar CMFBLSH (78.73) Submitted: 1/26/2018 11:34:35 AM : Outperform Start Price: $68.55 BPMC Score: -17.25

BLU-285's value supports entire EV of company right now (@ low $80's). It is a "miracle drug" in systemic mastocytosis and seems to work in well in some gastrointestinal stromal tumors (GIST). They have a huge library of kinases and the ability to modify them to reduce off-target interactions that cause toxicity issues. They may be the best. Success outside of BLU-285 is icing on the cake.

Another drug they have coming is BLU-667 that addresses a mutation called RET which is a driver of many cancers. LOXO has one too. But the RET market is very big to support two, especially if there is differentiation. May get some information on that at AACR in April or ASCO in June.

In a year or so, stock could be $150-200. Current: $83.83.


Find the members with the highest scoring picks in BPMC.

Score Leader


HDTVBG (< 20) Score: +216.65

The Score Leader is the player with the highest score across all their picks in BPMC.

Member Name Member
Call Time
Score Commentary
km00nster < 20 6/26/2015 Outperform 5Y $27.96 +100.07% +21.30% +78.77 0 Comment
gunterle 63.55 1/24/2017 Outperform 5Y $32.28 +73.30% +11.99% +61.31 0 Comment
jettyjett 39.75 5/30/2017 Outperform 5Y $35.50 +57.58% +5.58% +51.99 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 98.35 5/23/2017 Outperform 5Y $39.00 +43.44% +6.30% +37.13 0 Comment
AppleMoonbeam < 20 7/25/2017 Outperform 5Y $55.18 +1.39% +3.03% -1.64 0 Comment
curmie 75.99 11/5/2018 Outperform NS $65.92 -15.14% -6.37% -8.77 0 Comment
CMFBLSH 78.73 11/1/2017 Outperform 5Y $68.55 -18.40% -1.15% -17.25 1 Comment
usubanas2 91.09 9/27/2017 Outperform 5Y $66.88 -16.36% +2.33% -18.69 0 Comment
golfinflyr < 20 1/22/2018 Outperform 5Y $77.53 -27.85% -8.96% -18.89 0 Comment
Bigsef77 66.89 10/25/2017 10/9/2018 Outperform 3Y $69.70 -19.74% -0.43% -19.31 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BPMC.